Uncategorized
Ocular Therapeutix announces Q2 financial results
Ocular Therapeutix has announced its second-quarter financial results, which included a net loss attributable to common stockholders of approximately $6.4 million, or $2.10 per share, compared with $3.1 million, or $1.19 per share, during the same time last year.Q2 financial results also included $3.4 million in non-cash charges for stock-based compensation and licensing and consultant fees paid in common stock, compared with $0.2 million for similar charges in 2013, according to a company press release.